- Home
- SABS vs XAIR Comparison
SABS vs XAIR Comparison
Compare SABS & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SABS
- XAIR
- Stock Information
- Founded
- SABS 2014
- XAIR 2011
- Country
- SABS United States
- XAIR United States
- Employees
- SABS N/A
- XAIR N/A
- Industry
- SABS Biotechnology: Pharmaceutical Preparations
- XAIR Medical/Dental Instruments
- Sector
- SABS Health Care
- XAIR Health Care
- Exchange
- SABS Nasdaq
- XAIR Nasdaq
- Market Cap
- SABS 15.8M
- XAIR 17.0M
- IPO Year
- SABS N/A
- XAIR N/A
- Fundamental
- Price
- SABS $1.80
- XAIR $0.19
- Analyst Decision
- SABS Strong Buy
- XAIR Buy
- Analyst Count
- SABS 5
- XAIR 3
- Target Price
- SABS $11.80
- XAIR $1.50
- AVG Volume (30 Days)
- SABS 33.1K
- XAIR 5.1M
- Earning Date
- SABS 08-07-2025
- XAIR 06-17-2025
- Dividend Yield
- SABS N/A
- XAIR N/A
- EPS Growth
- SABS N/A
- XAIR N/A
- EPS
- SABS N/A
- XAIR N/A
- Revenue
- SABS $377,835.00
- XAIR $3,705,000.00
- Revenue This Year
- SABS N/A
- XAIR $286.75
- Revenue Next Year
- SABS N/A
- XAIR $144.39
- P/E Ratio
- SABS N/A
- XAIR N/A
- Revenue Growth
- SABS N/A
- XAIR 219.67
- 52 Week Low
- SABS $1.00
- XAIR $0.16
- 52 Week High
- SABS $5.01
- XAIR $1.49
- Technical
- Relative Strength Index (RSI)
- SABS 51.16
- XAIR 47.23
- Support Level
- SABS $1.60
- XAIR $0.18
- Resistance Level
- SABS $1.82
- XAIR $0.29
- Average True Range (ATR)
- SABS 0.11
- XAIR 0.03
- MACD
- SABS -0.01
- XAIR 0.00
- Stochastic Oscillator
- SABS 62.50
- XAIR 12.40
About SABS SAB Biotherapeutics Inc.
SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
About XAIR Beyond Air Inc.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.